Solifenacin Succinate Versus Fesoterodine A Comparison Trial for Urgency Symptoms
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01595152|
Recruitment Status : Unknown
Verified May 2012 by Lior Lowenstein, Rambam Health Care Campus.
Recruitment status was: Recruiting
First Posted : May 9, 2012
Last Update Posted : May 16, 2012
Objective 1: To advance the investigators understanding on the effect of solifenacin succinate (10 mg OD) vs. fesoterodine (8mg OD) on urinary urgency using a validated Urgency Severity and Impact Questionnaire (USIQ).
Hypothesis 1.1: The severity of urgency symptoms as measured by USIQ will change differently in women with OAB following a 3 month treatment with solifenacin succinate (10 mg OD) vs. fesoterodine (8mg OD).
Hypothesis 2.1: Condition-specific quality of life (QOL) as measured by USIQ will change differently in women with OAB following a 3 month treatment with solifenacin succinate (10 mg OD) vs. fesoterodine (8mg OD).
Objective 2: To advance the investigators understanding on the adverse events (AE's) of solifenacin succinate (10 mg OD) vs. fesoterodine (8mg OD).
Hypothesis 1.1: The severity and rate of AE's in women with OAB following a 3 month of treatment with solifenacin succinate (10 mg OD) vs. fesoterodine (8mg OD) will be different.
|Condition or disease||Intervention/treatment||Phase|
|Urinary Bladder, Overactive||Drug: solifenacin succinate Drug: fesoterodine||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||Solifenacin Succinate vs. Fesoterodine A Comparison Trial for the Treatment of Bothersome Urgency Symptoms|
|Study Start Date :||May 2012|
|Estimated Primary Completion Date :||May 2013|
|Estimated Study Completion Date :||May 2013|
|Active Comparator: solifenacin succinate (10 mg OD)||
Drug: solifenacin succinate
8 mg once daily for 60 days
Other Name: vesicare
|Active Comparator: fesoterodine (8mg OD)||
8 mg, once daily for 60 dyas
Other Name: Toviaz
- Changes in urgency sensation [ Time Frame: two months following treatment ]The effect of two different antochloinergic treatment on urgency symptoms will be measured by comparing USIQ scores changes in the two study arms, before and after treatment. Changes in urgency sensation will be analysed by subsiding the USIQ scopre at 2 months (second visit) from the USIQ score at baseline. Independent student t- test will be used for Comparison between the changes in USIQ score of the two groups.
- Adverse events [ Time Frame: two months ]Tolerability of both drugs will be monitored throughout the study based on reported AEs and discontinuations.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01595152
|Contact: Lior Lowenstein, MD, MSfirstname.lastname@example.org|
|Rambam Health Care Campus||Recruiting|
|Contact: Lior Lowenstein, MD 048542382 email@example.com|
|Hadassah||Not yet recruiting|
|Contact: David Shveiky, MD 97248542653 firstname.lastname@example.org|
|Principal Investigator: David Shveiky, MD|
|Belinson||Not yet recruiting|
|Petach Tikva, Israel|
|Contact: Haim Krissi, MD 97248542653 email@example.com|
|Principal Investigator: Haim Krissi, MD|
|Asaf harofeh||Not yet recruiting|
|Tel Aviv, Israel|
|Contact: Anna Padoa, MD 97248542653 firstname.lastname@example.org|
|Principal Investigator: Anna Padoa, MD|
|Rebecca Ziv||Not yet recruiting|
|Contact: Naama Marcus, MD 97248542653 email@example.com|
|Principal Investigator: Naama Marcus, MD|
|Principal Investigator:||Anna Padoa, MD||Assaf-Harofeh Medical Center|
|Principal Investigator:||Haim Krissi, MD||Belinson Medical center|
|Principal Investigator:||David Shveiky, MD||Hadassa|
|Principal Investigator:||Naama Marcus, MD||Rebecca ziv|
|Principal Investigator:||Lior Lowenstein, MD, MS||Rambam Health Care Campus|